Agios Pharmaceuticals
AGIO
197 hedge funds and large institutions have $2.47B invested in Agios Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 58 increasing their positions, 69 reducing their positions, and 32 closing their positions.
31% more call options, than puts
Call options by funds: $30.3M | Put options by funds: $23.1M
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% less funds holding
Funds holding: 198 → 197 (-1)
1.54% less ownership
Funds ownership: 102.84% → 101.3% (-1.5%)
16% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 69
25% less capital invested
Capital invested by funds: $3.3B → $2.47B (-$824M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$76.4M |
| 2 |
BlackRock
New York
|
+$29.4M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$19.1M |
| 4 |
JP Morgan Chase
New York
|
+$16.9M |
| 5 |
CC
Casdin Capital
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$44.6M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$25.2M |
| 3 |
HM
HealthCor Management
New York
|
-$13.3M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$13M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$10.8M |
AGIO Hedge Fund Activity: Q1 2020 in Review
197 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2020, worth a combined $2.47B — down 25% from $3.3B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AGIO positions and 32 closed out — a net gain of 1 holder — while 58 added to existing stakes and 69 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $76.4M. The largest seller was Ameriprise, cutting an estimated $44.6M.
- 197 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2020, down from 198 in Q4 2019.
- Funds reported $2.47B of Agios Pharmaceuticals stock for Q1 2020, down 25% quarter-over-quarter.
- 33 funds opened new Agios Pharmaceuticals positions in Q1 2020 and 32 closed out, a net change of +1 holder.
- The largest Agios Pharmaceuticals buyer in Q1 2020 was OrbiMed, an estimated $76.4M added.
- The largest Agios Pharmaceuticals seller in Q1 2020 was Ameriprise, an estimated $44.6M sold.
Based on aggregated 13F filings for Q1 2020.